No profile data available.
Tempest Therapeutics, Inc. (TPST) is a healthcare company in the additional cancer treatment drugs industry, based in Brisbane, United States, with about 4 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$26.26 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $12.84 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
Tempest Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$12.84 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include TScan Therapeutics, Inc. (TCRX), Actuate Therapeutics, Inc. Common stock (ACTU), AlphaTON Capital Corp. (ATON), Lantern Pharma Inc. (LTRN).